|
|
 |
|
|
CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)
Quiescent Hematopoietic Stem Cells are Activated by IFN-Gamma in Response to Chronic Infection
Here researchers show, using an in vivo mouse model of Mycobacterium avium infection, that an increased proportion of long-term repopulating hematopoietic stem cells proliferate during M. avium infection, and that this response requires interferon-gamma but not interferon-alpha signalling. [Nature]
Reprogramming of T Cells to Natural Killer-Like Cells upon Bcl11b Deletion
Here, researchers show that the transcription factor Bcl11b was expressed in all T cell compartments and was indispensable for T-lineage development. [Science]
Tumor-Induced Tolerance and Immune Suppression Depend on the C/EBP(Beta) Transcription Factor
Researchers showed that among factors produced by various experimental tumors, the cytokines GM-CSF, G-CSF, and IL-6 allowed a rapid generation of myeloid-derived suppressor cells from precursors present in mouse and human bone marrow. [Immunity]
Inhibition of Lipid Antigen Presentation in Dendritic Cells by HIV-1 Vpu Interference with CD1d Recycling from Endosomal Compartments
Given that the interaction with CD1d-expressing Dendritic cells is central to the ability of natural killer T (NKT) cells to regulate immunity, these data suggest that interference with the CD1d antigen presentation pathway represents an HIV-1 strategy to evade innate cellular immune responses, and imply a role for the innate-like CD1d-restricted NKT cells in the host defense against HIV-1. [Blood]
Allosteric Inhibition of Macrophage Migration Inhibitory Factor Revealed by Ibudilast
As described herein, the phosphodiesterase (PDE) inhibitor AV411 (ibudilast; 3-isobutyryl-2-isopropylpyrazolo-[1,5-a]pyridine) and its PDE-inhibition-compromised analog AV1013 inhibit the catalytic and chemotactic functions of the proinflammatory protein, macrophage migration inhibitory factor. [Proc Natl Acad Sci U S A]
Systemically Dispersed Innate IL-13-Expressing Cells in Type 2 Immunity
Here, researchers use IL-4 and IL-13 reporter mice to track lineage-negative innate cells that arise during type 2 immunity or in response to IL-25 and IL-33 in vivo. [Proc Natl Acad Sci U S A]
Identification of an IL-27/Osteopontin Axis in Dendritic Cells and its Modulation by IFN-Gamma Limits IL-17-Mediated Autoimmune Inflammation
The results identify a previously unknown pathway by which IFN-gamma limits IL-17-mediated autoimmune inflammation through differential regulation of osteopontin and IL-27 expression in dendritic cells. [Proc Natl Acad Sci U S A]
Enzymatically Active Single Chain Caspase-8 Maintains T Cell Survival During Clonal Expansion
Here, researchers show that caspase-8-deficient T cell survival was rescued by enzymatically active, but not inactive, casp8-expressing retroviruses. [Cell Death Differ]
TLR4-Mediated Skin Carcinogenesis is Dependent on Immune and Radioresistant Cells
The results suggest that the initial release of high mobility group box-1 protein triggers a TLR4-dependent inflammatory response that leads to tumour development. [EMBO J]
Control of T Cell Reactivation by Regulatory Qa-1-Restricted CD8+ T Cells
These experiments provide new insight into a CD8+ T cell compartment that regulates the immediate reactivation of conventional T cells and natural killer T cells. [J Immunol]
|
|
INDUSTRY NEWS
Idera Pharmaceuticals Announces Preliminary Data from Phase I Clinical Trial of IMO-3100, a Toll-like Receptor Antagonist Drug Candidate for Autoimmune and Inflammatory Diseases
Idera Pharmaceuticals, Inc. announced preliminary results from a Phase I clinical trial of IMO-3100, its lead Toll-like Receptor (TLR) 7 and TLR9 antagonist drug candidate for potential applications in autoimmune and inflammatory diseases. [Idera Pharmaceuticals, Inc. Press Release]
VBL Therapeutics Present Data on VB-201 for Rheumatoid Arthritis at EULAR Annual Meeting
VBL Therapeutics announced the presentation of preclinical data from the company's lead program, VB-201, at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology. [VBL Therapeutics Press Release]
Cytheris Closes $15 Million Series D Financing
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, announced that it has completed a $15 million Series D financing. [Cytheris SA Press Release]
The Iacocca Family Foundation and Kineta Announce New Partnership on Type I Diabetes Mellitus Drug Development Program
Kineta, Inc. joined with The Iacocca Family Foundation to announce a new investment partnership to speed development of Kineta's preclinical autoimmune drug candidate, ShK-186, and its multiple applications to treat Type I diabetes mellitus. [Kineta, Inc. Press Release]
|
|
POLICY NEWS
STAR METRICS: New Way to Measure the Impact of Federally Funded Research
A new initiative--Science and Technology for America's Reinvestment: Measuring the Effect of Research on Innovation, Competitiveness and Science, or STAR METRICS--promises to monitor the impact of federal science investments on employment, knowledge generation, and health outcomes. [National Institutes of Health, United States]
Market Withdrawal of GAMMAGARDLIQUID, Immune Globulin Intravenous (Human)
This voluntary market withdrawal is being conducted as a precautionary measure due to an increased number of adverse event reports of allergic reactions. [Food and Drug Administration, United States]
FDA Announces Collaboration with Drugs.com
The U.S. Food and Drug Administration announced that it will collaborate with the website Drugs.com to expand access to the FDA's consumer health information. [Food and Drug Administration, United States]
Administrative Supplements to Increase Public Awareness of Pediatric Cancers and Available Treatments and Research (NOT-CA-10-026) [National Institutes of Health, United States]
2010 Biological License Application Approvals [Food and Drug Administration, United States]
2010 Biological Device Application Approvals [Food and Drug Administration, United States]
|
|
EVENTS
Phacilitate Vaccine & Immunotherapy Forum 2010
June 21-23, 2010
Barcelona, Spain
Federation of Clinical Immunology Societies (FOCIS) 2010
June 24-27, 2010
Boston, United States
The Second International Conference on Regulatory T Cells and Th17 Cells and Clinical Application in Human Diseases
July 17-20, 2010
Shanghai, China
Frontiers in Immunology Research (FIRN) 2010 International Conference
July 22-26, 2010
Athens, Greece
14th International Congress of Immunology
August 22-27, 2010
Kobe, Japan
Select Biosciences 7th Annual RNAi & miRNA Europe
September 14-15, 2010
Dublin, Ireland
5th International Conference on Gene Regulation in Lymphocyte Development
October 9-14, 2010
Chania, Greece
Autumn Immunology Conference 2010
November 19-22, 2010
Chicago, United States
Cell Symposia: Influenza - Translating Basic Insights
December 2-4, 2010
Washington, D.C., United States
Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.
JOB OPPORTUNITIES
Senior Scientist - Magnetic Cell Separation (STEMCELL Technologies)
Business Development Manager Europe - Cell Therapy Products (Pall Corporation)
Sr. Product Support and Training Specialist (CardianBCT)
Manager/Sr. Manager, Therapeutic Cell Solutions, Process Development (Lonza)
Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization's career opportunities with Cell Therapy News.
Visit here to post your career opportunities.
Have we missed an important article or publication in Immune Regulation News? Click here to submit!
Comments or Suggestions? Email info@connexoncreative.com with your feedback.
|
|
|
|
|
|
|
|
|
